Clinical Trials

Sponsor: Novocure

Sponsor Study ID: TRIDENT/ EF-32

Study Title: Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

NCT Number: NCT04471844

Phase: N/A

Protocol Type: Treatment

Age Group: Adult

Disease Sites: Brain and Nervous System

Study Objectives: To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following radiation therapy.

If you would like to contact a MUSC study team member to learn more information about this study, click HERE.